This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Schering Aktiengesellschaft. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: The Innovative Contributions of Miriam E. C. Hancock
Introduction: Miriam E. C. Hancock is a distinguished inventor based in Oakland, CA, whose innovative work has significantly impacted the field of oncology. With a focus on identifying malignant tumors, her contributions have advanced diagnostic and therapeutic methods that are vital in cancer treatment.
Latest Patents: Miriam holds a notable patent titled "C-erbB-2 external domain: GP75." This patent discloses methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. It provides assays useful for diagnosing and prognosing neoplastic diseases by detecting the external domain of c-erbB-2, known as the glycoprotein gp75. The invention quantifies the level of gp75 in the biological fluids of mammals carrying a tumor burden. Additionally, it details recombinant, synthetically, and biologically produced novel proteins and polypeptides that are encoded by the c-erbB-2 oncogene. These gp75 proteins and polypeptides can be used therapeutically in cancer treatment, either alone or combined with chemotherapeutic agents. The patent also includes antibodies to gp75 proteins for diagnostic and therapeutic uses, along with test kits that embody the assays described.
Career Highlights: Miriam is currently associated with Schering Aktiengesellschaft, a firm renowned for its innovations in the pharmaceutical sector. Her work emphasizes the intersection of research and practical application in medicine, showcasing her commitment to enhancing cancer diagnostics and therapies.
Collaborations: In her professional journey, Miriam has collaborated with notable individuals like John J. Monahan and Beatrice Claudia Langton. These partnerships have enriched her research, contributing to the development of groundbreaking methods for cancer treatment.
Conclusion: Miriam E. C. Hancock is a pioneering inventor whose contributions to oncology have been instrumental in improving cancer diagnosis and treatment. Her patent on the c-erbB-2 external domain demonstrates her dedication to innovation in the medical field. Through her work at Schering Aktiengesellschaft and collaborations with esteemed colleagues, she is shaping the future of cancer therapeutics and diagnostics.